Mehls O, Haffner D, Wühl E, Tönshoff B, Schaefer F, Heinrich U
Division of Pediatric Nephrology, University Children's Hospital of Heidelberg, Germany.
Horm Res. 1996;46(4-5):230-5. doi: 10.1159/000185028.
Recombinant human growth hormone (rhGH) has become a new treatment modality for short children with chronic renal failure (CRF) and after renal transplantation. The rationale for high-dose rhGH treatment is the insensitivity of the uremic organism to GH. As the insensitivity to GH is expressed more in end-stage renal failure than in earlier stages of CRF, patients on dialysis respond less to rhGH. In transplanted children, rhGH can counterbalance the growth-depressing effects of corticosteroids. In prepubertal children, rhGH improves the height standard deviation score by a mean of +2 within 5 years. The effect of rhGH treatment on final height remains to be studied.
重组人生长激素（rhGH）已成为治疗慢性肾衰竭（CRF）患儿及肾移植后患儿身材矮小的一种新的治疗方式。大剂量rhGH治疗的理论依据是尿毒症机体对生长激素不敏感。由于对生长激素的不敏感性在终末期肾衰竭中比在CRF的早期阶段表现得更明显，接受透析的患者对rhGH的反应较小。在接受肾移植的儿童中，rhGH可以抵消皮质类固醇对生长的抑制作用。在青春期前儿童中，rhGH可使身高标准差评分在5年内平均提高2个单位。rhGH治疗对最终身高的影响仍有待研究。
